The drug, called Yeztugo from company Gilead Sciences, was approved Wednesday based on data from clinical trials that showed 99.9% of participants who received it remained HIV negative.

Fingerprint-based drug tests now used at 20+ Managed Waste Service sites in New South Wales. Results from Intelligent Bio’s system delivered in under 10 minutes on-site. Geopolitical tensions ...

FDA offers speedier approvals to drug companies aligning with 'national priorities' by Stephanie Brown edited by Gaby Clark, reviewed by Andrew Zinin Editors' notes ...

Given FD&C colors have a longstanding history of approval by the U.S. Food & Drug Administration, Kraft Heinz has used the colors in a small number of products.

Researchers from the George Washington University have uncovered promising evidence in an animal study that shows setmelanotide, an FDA-approved medication for a rare genetic obesity disorder, may ...

Visit Upsher-Smith at the PPMD 2025 Annual Conference Resource Fair to Learn More About Support Services and Resources Offered for Deflazacort Tablets MAPLE GROVE, Minn., June 16, 2025 /PRNewswire/ -- ...

Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced ...

FLORHAM PARK, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ...

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032 ...

FLORHAM PARK, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ...

FLORHAM PARK, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ...